FZD7 and neoplasm: For example, antibodies targeting the extracellular domain of FZD5, FZD7, and FZD10 have been successfully applied to inhibit the individual FZD-induced tumor growth in pancreatic ductal adenocarcinoma, Wilms’ tumor, and synovial sarcoma, respectively (69–71).